Swedish Orphan Biovitrum AB

Type: Company
Name: Swedish Orphan Biovitrum AB (Biovitrum AB)
Nationality: Sweden
Web Address: http://www.biovitrum.com/
Fact Sheet: Fact Sheet for Biovitrum AB
First reported Jul 23 2014 - Updated Jul 23 2014 - 2 reports

Biogen Idec’s 2nd-qtr 40% revenues growth beats forecasts

Shares of US biotech firm Biogen Idec (Nasdaq: BIIB) jumped 7.35% to $326 in pre-market trading today, as the company reported second-quarter 2014 financial results showing that sales had increased 40% to $2.42 billion, well above the average forecast ... [Published Pharma Letter - Jul 23 2014]
First reported Jul 18 2014 - Updated Jul 19 2014 - 6 reports

Sobi increases revenue by 27%

Swedish Orphan Biovitrum AB increased revenue by 27% in the second quarter on the back of demand for its rare disease therapy Orfadin for hereditary tyrosinaemia type 1. During the quarter, Sobi and it partner Biogen also received FDA approval for a new ... [Published MedNous - Jul 19 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Swedish Orphan Biovitrum publ AB maintains FY 2014 financial guidance

7:00am BST Swedish Orphan Biovitrum publ AB:Says it continues to expect the company's total revenues for FY 2014 to be in the range of between 2,300 mln Swedish crowns and 2,500 mln crowns.FY 2014 gross margin is expected to be in the range of between ... [Published Reuters UK - Jul 18 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 1 reports

BB Biotech Q2 Profit Climbs - Quick Facts

BB Biotech AG (BBAGF.PK), a Swiss investment company in the biotechnology industry, reported Thursday that its second-quarter net gain increased to 195.425 million Swiss francs from last year's 134.091 million francs.Profit per share was 17.23 francs, ... [Published RTTNews.com - Jul 17 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 1 reports

BB BIOTECH AG: Biotech sector recovers from market correction - new products and M&A the main drivers

BB BIOTECH AG /BB BIOTECH AG: Biotech sector recovers from market correction - new products andM&A the main drivers. Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.Interim ... [Published EuroInvestor - Jul 17 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 2 reports

Invitation - Presentation of Sobi's second quarter results 2014

On 18 July Swedish Orphan Biovitrum AB (publ) (Sobi) will publish its report for the second quarter 2014.Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, at 12:30 p.m. ... [Published OSIX News - Jul 09 2014]
First reported Jul 04 2014 - Updated Jul 04 2014 - 1 reports

Sobi files for label extension of Xiapex with EMA for Peyronie's indication

(MarketLine via COMTEX News Network) -- Auxilium Pharmaceuticals, Inc., a biopharmaceutical company, has announced that Swedish Orphan Biovitrum AB, or Sobi, a pharmaceutical company, has filed for an extension of the label for Xiapex with the European ... [Published PredictWallStreet - Jul 04 2014]
First reported Jun 26 2014 - Updated Jun 27 2014 - 2 reports

Sobi seeks European approval of Xiapex for Peyronies disease

Swedish Orphan Biovitrum (Sobi) has filed for an extension of the label for Xiapex (collagenase clostridium histolyticum) with the European Medicines Agency to include the indication of Peyronie's disease.The European filing is supported by positive data ... [Published Pharmaceutical Technology - Jun 27 2014]
First reported Jun 26 2014 - Updated Jun 26 2014 - 3 reports

Sobi files for EU approval of Xiapex for Peyronies disease

Release date- 25062014 - Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. today announced that Sobi has filed for an extension of the label for Xiapex (collagenase clostridium histolyticum) with the European Medicines Agency ... [Published Pharmacy Choice - Jun 26 2014]
First reported May 12 2014 - Updated May 13 2014 - 4 reports

Biogen, Sobi pledge hemophilia drug donation in developing world

Biogen Idec Inc and partner Swedish Orphan Biovitrum AB on Monday said they will donate hemophilia drugs for use in developing nations in quantities large enough to treat tens of thousands of patients over the next decade. The potentially life-sa... ... [Published Yahoo! Health News - May 12 2014]
First reported Apr 14 2014 - Updated Apr 15 2014 - 2 reports

Auxilium, Sobi present data from clinical trials evaluating the use of Xiaflex/Xiapex in adult patients with PD at EAU Congress

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, and Swedish Orphan Biovitrum AB (Sobi), an international specialty healthcare company dedicated to rare diseases, have presented encore data from multiple clinical ... [Published PharmaBiz - Apr 15 2014]
First reported Apr 10 2014 - Updated Apr 11 2014 - 3 reports

Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety Results from Phase 3 Pediatric Study of Investigational Therapy Eloctate™ (rFVIIIFc) for Hemophilia A

CAMBRIDGE, Mass. & STOCKHOLM--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today released positive top-line results of the Kids A-LONG Phase 3 clinical study that evaluated the safety and efficacy ... [Published Business Wire Photo/Multimedia News - Apr 10 2014]

Quotes

...However, the "debate is being driven much more by midterm election politics than policy differences" and is unlikely to result in any legitimate actions before the election
Geoffrey McDonough, chief executive and president, said: "The second quarter marks a solid mid-year position for the company with balanced growth across the commercial portfolio. From a development perspective, our long-acting factors for hemophilia received several regulatory approvals in collaborator Biogen Idec's territories, helping move these programs into a pre-launch phase for the company, pending Sobi's opt-in later this year."
"The second quarter marks a solid mid-year position for the company with balanced growth across the commercial portfolio" , said Geoffrey McDonough, CEO
"ELOCTATE and ALPROLIX are poised to capture a significant share of the hemophilia market and also grow the market by increasing prophylactic treatment,” researchers wrote at the time."

More Content

All (93) | News (48) | Reports (0) | Blogs (15) | Audio/Video (0) | Fact Sheets (2) | Press Releases (27)
sort by: Date | Relevance
European Medicines Agency renews Marketing Auth... [Published Ysios Capital Partners - Jul 25 2014]
Biogen Idec’s 2nd-qtr 40% revenues growth beats... [Published Pharma Letter - Jul 23 2014]
Biogen Idec Second Quarter 2014 Revenues Increa... [Published Tamar Securities - Jul 23 2014]
Pre-Filled Syringes Market (2nd Edition), 2014 ... [Published RCL Advisors - Jul 21 2014]
FirstWord Lists: Pharma's tax inversion craze h... [Published FirstWord Pharma - Jul 20 2014]
Sobi increases revenue by 27% [Published MedNous - Jul 19 2014]
Sobi revenues up 27% in 2nd-qtr 2014 [Published Pharma Letter - Jul 18 2014]
Swedish Orphan Biovitrum publ AB maintains FY 2... [Published Reuters UK - Jul 18 2014]
Sobi's board of directors exercises authorisati... [Published GlobeNewswire: Acquisitions News - Jul 18 2014]
Sobi Reports Profit In Q2; 2014 Outlook Unchang... [Published RTTNews.com - Jul 18 2014]
Sobi publishes Report for the Second Quarter 2014 [Published Industrial Info Financials - Jul 18 2014]
Sobi publishes Report for the Second Quarter 2014 [Published MyNewsDesk - Jul 18 2014]
Sobi publishes Report for the Second Quarter 2014 [Published BusinessWeek - Jul 18 2014]
Biogen poised to shake up hemophilia market [Published Medical Marketing And Media - Jul 17 2014]
BB Biotech Q2 Profit Climbs - Quick Facts [Published RTTNews.com - Jul 17 2014]
BB BIOTECH AG: Biotech sector recovers from mar... [Published EuroInvestor - Jul 17 2014]
Roche to Provide Exclusive Update on Biologic T... [Published Ein News - Jul 14 2014]
European Medicines Agency renews Marketing Auth... [Published Noodls - Jul 10 2014]
Invitation - Presentation of Sobi's second quar... [Published OSIX News - Jul 09 2014]
Invitation - Presentation of Sobi's second quar... [Published Nasdaq - Jul 09 2014]
Sobi files for label extension of Xiapex with E... [Published PredictWallStreet - Jul 04 2014]
Diabetic Neuropathic Pain Clinical Trials H1 Gl... [Published Individual.com - Jul 02 2014]
First Long-Acting Drug For Haemophilia A Approv... [Published FirstWord Pharma - Jul 02 2014]
Sobi awarded Company of the Year at the Europea... [Published GlobeNewswire: Acquisitions News - Jul 01 2014]
Sobi seeks European approval of Xiapex for Peyr... [Published Pharmaceutical Technology - Jun 27 2014]
BioSpecifics Technologies Corp. to Be Added to ... [Published Staten Island Live - Jun 27 2014]
Auxilium/Sobi's Xiapex Filed for Label Expansion [Published Yahoo! Finance - Jun 26 2014]
Sobi files for EU approval of Xiapex for Peyron... [Published Pharmacy Choice - Jun 26 2014]
BioSpecifics Technologies' marketing approval o... [Published Individual.com - Jun 26 2014]
Sobi seeks EMA approval for Xiapex for Peyronie... [Published PBR - News - Jun 26 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Sobi seeks EMA approval for Xiapex for Peyronie... [Published PBR - News - Jun 26 2014]
Swedish Orphan Biovitrum (Sobi) has filed for an extension of the label for Xiapex with the European Medicines Agency (EMA) to include the indication of Peyronie's disease. ...
BioSpecifics Technologies Corp. Announces Filin... [Published PR Newswire: Health - Jun 25 2014]
LYNBROOK, N.Y., June 25, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, announced today that ...
Sobi files for EU approval of Xiapex for Peyron... [Published PR Newswire: Financial Services - Jun 25 2014]
STOCKHOLM and CHESTERBROOK, Pa., June 25, 2014 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. today announced that Sobi has filed for an extension of the label for Xiapex® (collagenase clostridium histolyticum) ...
ORFADIN (Nitisinone) Capsule [SWEDISH ORPHAN BI... [Published DailyMed Drug Label Updates for the last seven ... - Jun 15 2014]
Updated Date: Jun 11, 2014 EST ...
Biogen, Sobi pledge hemophilia drug donation in... [Published Yahoo! Health News - May 12 2014]
Biogen Idec Inc and partner Swedish Orphan Biovitrum AB on Monday said they will donate hemophilia drugs for use in developing nations in quantities large enough to treat tens of thousands of patients over the next decade. The potentially life-sa... ...
1 2 3

Press Releases

sort by: Date | Relevance
Sobi's board of directors exercises authorisati... [Published GlobeNewswire: Acquisitions News - Jul 18 2014]
Sobi awarded Company of the Year at the Europea... [Published GlobeNewswire: Acquisitions News - Jul 01 2014]
Sobi files for EU approval of Xiapex for Peyron... [Published GlobeNewswire: Advertising News - Jun 25 2014]
Sobi to review preclinical data to potentially ... [Published GlobeNewswire: Acquisitions News - Jun 16 2014]
The US Food and Drug Administration (FDA) appro... [Published GlobeNewswire: Advertising News - Jun 09 2014]
1 2 3 4 5 6
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.